Skip to content

Study · Randomized controlled trial · n = 109 · 2015

10 results

A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks.

Bowen RL, Perry G, Xiong C, Smith MA, Atwood CS

Journal of Alzheimer's disease : JAD1 Jan 2015Cited by 48 (Europe PMC)

PMID25310993 (opens in a new tab)DOI10.3233/jad-141626 (opens in a new tab)PepBankPUB-25310993
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with Alzheimer's disease, ADAS-Cog showed no statistically significant difference among low-dose leuprolide, high-dose leuprolide and placebo, with a non-statistically significant trend favoring high-dose leuprolide.

    In plain wordsIn women with Alzheimer's disease, cognitive scores did not differ significantly between leuprolide and placebo; high-dose showed a non-significant trend in its favor.

    Peptide
    Leuprolide
    Outcome
    No significant changeADAS-Cog
    Study

    n = 109

    Comparator
    Other randomized groups including placebo
    Analysis
    Primary
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    11.25 mg or 22.5 mg · injection every 12 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences in primary efficacy parameters (ADAS-Cog and ADCS-CGIC), although there was a non-statistically significant trend in favor of the high dose Lupron group on the ADAS-Cog.
    2 context sentences
    Summary · context
    To test the efficacy and safety of leuprolide acetate (Lupron Depot) in the treatment of Alzheimer's disease (AD), we conducted a 48-week, double-blind, placebo-controlled, dose-ranging study in women aged 65 years or older with mild to moderate AD.
    Summary · context
    A total of 109 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 24 inclusive were randomized to low dose Lupron Depot (11.25 mg leuprolide acetate), high dose Lupron Depot (22.5 mg leuprolide acetate), or placebo injections every 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with Alzheimer's disease, ADCS-CGIC did not differ significantly among leuprolide dose groups and placebo.

    In plain wordsIn women with Alzheimer's disease, global clinical scores did not differ significantly between leuprolide groups and placebo.

    Peptide
    Leuprolide
    Outcome
    No significant changeADCS-CGIC
    Study

    n = 109

    Comparator
    Other randomized groups including placebo
    Analysis
    Primary
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    11.25 mg or 22.5 mg · injection every 12 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences in primary efficacy parameters (ADAS-Cog and ADCS-CGIC), although there was a non-statistically significant trend in favor of the high dose Lupron group on the ADAS-Cog.
    2 context sentences
    Summary · context
    To test the efficacy and safety of leuprolide acetate (Lupron Depot) in the treatment of Alzheimer's disease (AD), we conducted a 48-week, double-blind, placebo-controlled, dose-ranging study in women aged 65 years or older with mild to moderate AD.
    Summary · context
    A total of 109 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 24 inclusive were randomized to low dose Lupron Depot (11.25 mg leuprolide acetate), high dose Lupron Depot (22.5 mg leuprolide acetate), or placebo injections every 12 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with Alzheimer's disease, secondary efficacy parameters did not differ significantly among leuprolide dose groups and placebo.

    In plain wordsIn women with Alzheimer's disease, secondary outcomes did not differ significantly between leuprolide groups and placebo.

    Peptide
    Leuprolide
    Outcome
    No significant changeNPI, ADCS-ADL, BI and ADCS-Severity Rating
    Study

    n = 109

    Comparator
    Other randomized groups including placebo
    Analysis
    Secondary
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    11.25 mg or 22.5 mg · injection every 12 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences in secondary efficacy parameters (NPI, ADCS-ADL, BI, and ADCS-Severity Rating).
    2 context sentences
    Summary · context
    To test the efficacy and safety of leuprolide acetate (Lupron Depot) in the treatment of Alzheimer's disease (AD), we conducted a 48-week, double-blind, placebo-controlled, dose-ranging study in women aged 65 years or older with mild to moderate AD.
    Summary · context
    A total of 109 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 24 inclusive were randomized to low dose Lupron Depot (11.25 mg leuprolide acetate), high dose Lupron Depot (22.5 mg leuprolide acetate), or placebo injections every 12 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with Alzheimer's disease taking AChEIs, high-dose leuprolide reduced ADAS-Cog decline versus placebo: 0.18 versus 3.30.

    In plain wordsIn women taking AChEIs for Alzheimer's disease, high-dose leuprolide reduced cognitive decline compared with placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseADAS-Cog in AChEI subgroup
    Study

    n: not reported in source

    Comparator
    Placebo with AChEI
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    22.5 mg · injection every 12 weeks · 48 weeksAs given in this study (human).

    Measurements

    ADAS-Cog mean decline
    0.18 points
    high-dose leuprolide (22.5 mg), AChEI subgroup
    ADAS-Cog mean decline
    4.21 points
    low-dose leuprolide (11.25 mg), AChEI subgroup
    ADAS-Cog mean decline
    3.3 points
    placebo, AChEI subgroup

    Source sentences

    Summary
    However, in the a priori designated subgroup analysis of patients taking an acetylcholinesterase inhibitor (AChEI), there was a statistically significant benefit in the high dose group compared to both the low dose and placebo groups
    3 context sentences
    Summary · context
    as determined by ADAS-Cog (mean decline: 0.18, 4.21, and 3.30)
    Summary · context
    To test the efficacy and safety of leuprolide acetate (Lupron Depot) in the treatment of Alzheimer's disease (AD), we conducted a 48-week, double-blind, placebo-controlled, dose-ranging study in women aged 65 years or older with mild to moderate AD.
    Summary · context
    A total of 109 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 24 inclusive were randomized to low dose Lupron Depot (11.25 mg leuprolide acetate), high dose Lupron Depot (22.5 mg leuprolide acetate), or placebo injections every 12 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with Alzheimer's disease taking AChEIs, high-dose leuprolide reduced ADAS-Cog decline versus low-dose leuprolide: 0.18 versus 4.21.

    In plain wordsIn women taking AChEIs for Alzheimer's disease, high-dose leuprolide reduced cognitive decline compared with low-dose leuprolide.

    Peptide
    Leuprolide
    Outcome
    DecreaseADAS-Cog in AChEI subgroup
    Study

    n: not reported in source

    Comparator
    11.25 mg leuprolide with AChEI
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    22.5 mg · injection every 12 weeks · 48 weeksAs given in this study (human).

    Measurements

    ADAS-Cog mean decline
    0.18 points
    high-dose leuprolide (22.5 mg), AChEI subgroup
    ADAS-Cog mean decline
    4.21 points
    low-dose leuprolide (11.25 mg), AChEI subgroup
    ADAS-Cog mean decline
    3.3 points
    placebo, AChEI subgroup

    Source sentences

    Summary
    However, in the a priori designated subgroup analysis of patients taking an acetylcholinesterase inhibitor (AChEI), there was a statistically significant benefit in the high dose group compared to both the low dose and placebo groups
    3 context sentences
    Summary · context
    as determined by ADAS-Cog (mean decline: 0.18, 4.21, and 3.30)
    Summary · context
    To test the efficacy and safety of leuprolide acetate (Lupron Depot) in the treatment of Alzheimer's disease (AD), we conducted a 48-week, double-blind, placebo-controlled, dose-ranging study in women aged 65 years or older with mild to moderate AD.
    Summary · context
    A total of 109 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 24 inclusive were randomized to low dose Lupron Depot (11.25 mg leuprolide acetate), high dose Lupron Depot (22.5 mg leuprolide acetate), or placebo injections every 12 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with Alzheimer's disease taking AChEIs, clinical decline occurred in 38% with high-dose leuprolide versus 63% with placebo.

    In plain wordsIn women taking AChEIs for Alzheimer's disease, clinical decline was less frequent with high-dose leuprolide than placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseADCS-CGIC decline in AChEI subgroup
    Study

    n: not reported in source

    Comparator
    Placebo with AChEI
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    22.5 mg · injection every 12 weeks · 48 weeksAs given in this study (human).

    Measurements

    Subjects experiencing decline on ADCS-CGIC
    38%
    high-dose leuprolide, AChEI subgroup
    Subjects experiencing decline on ADCS-CGIC
    82%
    low-dose leuprolide, AChEI subgroup
    Subjects experiencing decline on ADCS-CGIC
    63%
    placebo, AChEI subgroup

    Source sentences

    Summary
    However, in the a priori designated subgroup analysis of patients taking an acetylcholinesterase inhibitor (AChEI), there was a statistically significant benefit in the high dose group compared to both the low dose and placebo groups
    3 context sentences
    Summary · context
    ADCS-CGIC (% subjects experiencing decline: 38, 82, and 63)
    Summary · context
    To test the efficacy and safety of leuprolide acetate (Lupron Depot) in the treatment of Alzheimer's disease (AD), we conducted a 48-week, double-blind, placebo-controlled, dose-ranging study in women aged 65 years or older with mild to moderate AD.
    Summary · context
    A total of 109 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 24 inclusive were randomized to low dose Lupron Depot (11.25 mg leuprolide acetate), high dose Lupron Depot (22.5 mg leuprolide acetate), or placebo injections every 12 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with Alzheimer's disease taking AChEIs, clinical decline occurred in 38% with high-dose leuprolide versus 82% with low-dose leuprolide.

    In plain wordsIn women taking AChEIs for Alzheimer's disease, clinical decline was less frequent with high-dose than low-dose leuprolide.

    Peptide
    Leuprolide
    Outcome
    DecreaseADCS-CGIC decline in AChEI subgroup
    Study

    n: not reported in source

    Comparator
    11.25 mg leuprolide with AChEI
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    22.5 mg · injection every 12 weeks · 48 weeksAs given in this study (human).

    Measurements

    Subjects experiencing decline on ADCS-CGIC
    38%
    high-dose leuprolide, AChEI subgroup
    Subjects experiencing decline on ADCS-CGIC
    82%
    low-dose leuprolide, AChEI subgroup
    Subjects experiencing decline on ADCS-CGIC
    63%
    placebo, AChEI subgroup

    Source sentences

    Summary
    However, in the a priori designated subgroup analysis of patients taking an acetylcholinesterase inhibitor (AChEI), there was a statistically significant benefit in the high dose group compared to both the low dose and placebo groups
    3 context sentences
    Summary · context
    ADCS-CGIC (% subjects experiencing decline: 38, 82, and 63)
    Summary · context
    To test the efficacy and safety of leuprolide acetate (Lupron Depot) in the treatment of Alzheimer's disease (AD), we conducted a 48-week, double-blind, placebo-controlled, dose-ranging study in women aged 65 years or older with mild to moderate AD.
    Summary · context
    A total of 109 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 24 inclusive were randomized to low dose Lupron Depot (11.25 mg leuprolide acetate), high dose Lupron Depot (22.5 mg leuprolide acetate), or placebo injections every 12 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In women with Alzheimer's disease taking AChEIs, ADCS-ADL mean decline was -0.54 with high-dose leuprolide versus -6.85 with placebo.

    In plain wordsIn women taking AChEIs for Alzheimer's disease, daily function declined less with high-dose leuprolide than placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseADCS-ADL decline in AChEI subgroup
    Study

    n: not reported in source

    Comparator
    Placebo with AChEI
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    22.5 mg · injection every 12 weeks · 48 weeksAs given in this study (human).

    Measurements

    ADCS-ADL mean decline
    −0.54 points
    high-dose leuprolide, AChEI subgroup
    ADCS-ADL mean decline
    −8 points
    low-dose leuprolide, AChEI subgroup
    ADCS-ADL mean decline
    −6.85 points
    placebo, AChEI subgroup

    Source sentences

    Summary
    However, in the a priori designated subgroup analysis of patients taking an acetylcholinesterase inhibitor (AChEI), there was a statistically significant benefit in the high dose group compared to both the low dose and placebo groups
    3 context sentences
    Summary · context
    and ADCS-ADL (mean decline: -0.54, -8.00, and -6.85), respectively.
    Summary · context
    To test the efficacy and safety of leuprolide acetate (Lupron Depot) in the treatment of Alzheimer's disease (AD), we conducted a 48-week, double-blind, placebo-controlled, dose-ranging study in women aged 65 years or older with mild to moderate AD.
    Summary · context
    A total of 109 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 24 inclusive were randomized to low dose Lupron Depot (11.25 mg leuprolide acetate), high dose Lupron Depot (22.5 mg leuprolide acetate), or placebo injections every 12 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In women with Alzheimer's disease taking AChEIs, ADCS-ADL mean decline was -0.54 with high-dose leuprolide versus -8.00 with low-dose leuprolide.

    In plain wordsIn women taking AChEIs for Alzheimer's disease, daily function declined less with high-dose than low-dose leuprolide.

    Peptide
    Leuprolide
    Outcome
    DecreaseADCS-ADL decline in AChEI subgroup
    Study

    n: not reported in source

    Comparator
    11.25 mg leuprolide with AChEI
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    22.5 mg · injection every 12 weeks · 48 weeksAs given in this study (human).

    Measurements

    ADCS-ADL mean decline
    −0.54 points
    high-dose leuprolide, AChEI subgroup
    ADCS-ADL mean decline
    −8 points
    low-dose leuprolide, AChEI subgroup
    ADCS-ADL mean decline
    −6.85 points
    placebo, AChEI subgroup

    Source sentences

    Summary
    However, in the a priori designated subgroup analysis of patients taking an acetylcholinesterase inhibitor (AChEI), there was a statistically significant benefit in the high dose group compared to both the low dose and placebo groups
    3 context sentences
    Summary · context
    and ADCS-ADL (mean decline: -0.54, -8.00, and -6.85), respectively.
    Summary · context
    To test the efficacy and safety of leuprolide acetate (Lupron Depot) in the treatment of Alzheimer's disease (AD), we conducted a 48-week, double-blind, placebo-controlled, dose-ranging study in women aged 65 years or older with mild to moderate AD.
    Summary · context
    A total of 109 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 24 inclusive were randomized to low dose Lupron Depot (11.25 mg leuprolide acetate), high dose Lupron Depot (22.5 mg leuprolide acetate), or placebo injections every 12 weeks.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In women with Alzheimer's disease taking AChEIs, NPI, ADCS-CGI Severity Rating, and BI did not differ between treatment groups.

    In plain wordsIn women taking AChEIs for Alzheimer's disease, these behavioral and severity measures did not differ between leuprolide and other treatment groups.

    Peptide
    Leuprolide
    Outcome
    No significant changeNPI, ADCS-CGI Severity Rating and BI in AChEI subgroup
    Study

    n: not reported in source

    Comparator
    Other treatment groups in AChEI subgroup
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    11.25 mg or 22.5 mg · injection every 12 weeks · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    No differences between treatment groups were seen on the NPI, ADCS-CGI Severity Rating, or the BI in the subgroup analysis.
    2 context sentences
    Summary · context
    To test the efficacy and safety of leuprolide acetate (Lupron Depot) in the treatment of Alzheimer's disease (AD), we conducted a 48-week, double-blind, placebo-controlled, dose-ranging study in women aged 65 years or older with mild to moderate AD.
    Summary · context
    A total of 109 women with mild to moderate AD and a Mini-Mental State Examination score between 12 and 24 inclusive were randomized to low dose Lupron Depot (11.25 mg leuprolide acetate), high dose Lupron Depot (22.5 mg leuprolide acetate), or placebo injections every 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.